• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Special Reports
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Resources
    • About MassDevice
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
    • In-Depth Coverage
    • Latest News
  • Attend DeviceTalks
    • Events
      • DeviceTalks Minnesota – May 4
      • DeviceTalks Boston – May 27–28
      • DeviceTalks West
      • DeviceTalks Tuesdays
    • DeviceTalks Podcast Network
      • DeviceTalks Weekly
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Advertise
  • Subscribe
Home » Abbott plans $38m Mitraclip plant in Indiana

Abbott plans $38m Mitraclip plant in Indiana

October 29, 2019 By Sean Whooley

AbbottAbbott (NYSE:ABT) announced yesterday that it plans to spend close to $38 million to open a manufacturing plant for its Mitraclip system in Westfield, Ind.

The proposed 120,000-square-foot facility in Westfield’s NorthPoint Industrial Park could cost more than $37.6 million and is slated to employ as many as 477 people by the end of 2024, according to the Indianapolis Business Journal. The company expects construction to begin this year and plans to have the facility fully functioning by 2021.

The MitraClip is a transcatheter heart valve repair device designed to treat mitral regurgitation. It secured its first FDA approval in 2013 and won FDA approval for its most advanced version, the MitraClip G4, in August. Indiana will join California as the second state to manufacture the device when the facility is completed.

Jobs at the new facility are expected to include assemblers, technicians and engineers with an average wage of $27 per hour.

The IBJ reported that Abbott conducted an internal search before choosing the location, and the Westfield City Council approved 10-year real and personal property tax abatements for the company last night.

The Indiana Economic Development Corp. offered up to $3.5 million in conditional tax credits along with $1 million in training grants because of Abbott’s intention to create more than 300 jobs before 2024 ends. The incentives are contingent upon Abbott meeting the hiring marks. IEDC’s offer of up to $750,000 to improve infrastructure in the area is under consideration.

“We’re pleased to expand our U.S. presence by building an additional MitraClip manufacturing facility in Indiana,” VP of Abbott’s structural heart business Mike Dale said in prepared remarks. “This facility will help in our goal to improve the health of people around the world and meet the needs of physicians and patients battling structural heart disease,”

“This is a great day for the city of Westfield,” added Mayor Andy Cook. “We have worked hard to attract diverse businesses. The addition of a Fortune 500 life sciences company, like Abbott, is a big win not only for Westfield but for the state of Indiana.”

Shares of ABT were up 0.5% at 83.08 per share in mid-morning trading today.

Filed Under: Business/Financial News, Cardiac Implants, Catheters Tagged With: Abbott

More recent news

  • Sequel Med Tech’s automated twiist pump scores FDA clearance in type 2 diabetes
  • FDA posts alert for Edwards Lifesciences mitral valve delivery system after patient death
  • Former Medtronic RDN leader joins Teleflex
  • CMR Surgical CEO outlines the path forward for Stryker’s robotics partnership
  • Stryker earns FDA clearance for new bone and soft tissue removal platform

About Sean Whooley

Sean Whooley is a senior editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at [email protected].

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >
MDO ad
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2026 · Arrowfly LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly.

Privacy Policy